Professor Sanjay Popat

Consultant Medical Oncologist BSc MBBS FRCP PhD

Specialism: Lung

Available at: Chelsea

Special interests:

  • lung cancer
  • mesothelioma
  • thymoma

Biography

Professor Popat has both a private and an NHS practice at The Royal Marsden. Professor Sanjay Popat is a Consultant Thoracic Medical Oncologist at The Royal Marsden and Honorary Clinical Senior Lecturer in the Molecular Genetics and Genomics Group at the National Heart and Lung Institute, Imperial College London.

He is a specialist thoracic oncologist, and is an internationally recognised expert in the treatment of lung cancer, mesothelioma and cancers of the thymus (thymoma and thymic carcinoma). Sanjay qualified from Guy’s and St Thomas’ Hospitals in 1994, completed general medical training at the Royal Brompton and the Hammersmith Hospital, and medical oncology training at The Royal Marsden. He was awarded a PhD in Molecular Genetics in 2002 and thereafter undertook a postdoctoral Clinician Scientist Fellowship, and subsequently a HEFCE Clinical Senior Lectureship. He has published in the fields of molecular genetics, therapeutic biomarkers and medical oncology. He has been awarded nationally and internationally competitive prizes for his research, in addition to four research fellowships.

His research interests include identification and validation of DNA variants that influence thoracic tumour development and their impact on clinical behaviour, the identification of biomarkers predictive of therapeutic effect, as well as the development of novel therapeutic strategies for the treatment of thoracic tumours through clinical trials.

He is Chair of the British Thoracic Oncology Group (BTOG), and also the Advanced Diseases Sub-group of the UK NCRI Lung Cancer Clinical Studies Group. He is Cancer Divisional Co-Director of the NIHR-London South Clinical Research Network. He is active in the European Organisation for Research and Treatment of Cancer (EORTC) Lung Group, the European Thoracic Oncology Platform (ETOP), and the International Thymic Malignancy Interest Group (ITMIG).

Clinical units